OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN and Stefan RUTKOWSKI. Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group. Klinische Pädiatrie. Stuttgart: Georg Thieme Verlag, 2023, vol. 235, No 3, p. 167-177. ISSN 0300-8630. Available from: https://dx.doi.org/10.1055/a-2070-7572.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group
Authors OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN and Stefan RUTKOWSKI.
Edition Klinische Pädiatrie, Stuttgart, Georg Thieme Verlag, 2023, 0300-8630.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW SIOP
Impact factor Impact factor: 1.000 in 2022
RIV identification code RIV/00216224:90249/23:00132052
Doi http://dx.doi.org/10.1055/a-2070-7572
UT WoS 001058665800004
Keywords (in Czech) ependymoma; guideline; radiotherapy; chemotherapy; children
Keywords in English ependymoma; guideline; radiotherapy; chemotherapy; children
Tags Excelence Science, INT, neMU, RIV, user, článek v časopise
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 12/4/2024 12:58.
Abstract
Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged > 1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 20/5/2024 01:20